Estradiol Doesn't Boost Cognitive Function After Menopause

This article originally appeared here.
Share this content:
Estradiol Doesn't Boost Cognitive Function After Menopause
Estradiol Doesn't Boost Cognitive Function After Menopause

THURSDAY, July 21, 2016 (HealthDay News) -- Improvement in cognitive ability is not associated with estrogen therapy among women who use it after menopause, no matter when they start taking it, according to a study published online July 15 in Neurology.

Victor Henderson, M.D., of the Stanford University School of Medicine in Palo Alto, Calif., and colleagues randomly assigned 567 healthy women, aged 41 to 84, to take estradiol or an inactive placebo every day. In addition, the women were divided into two groups: an early menopause group (within six years of their last period) and a late group (at least 10 years after menopause). The women also used a vaginal progesterone gel or placebo gel, unless they had had a hysterectomy. The average treatment lasted nearly five years. The investigators tested the verbal memory and cognitive skills of the participants at the beginning of the trial, 2.5 years later, and five years later.

The researchers found that, compared with starting scores on memory tests, women improved in verbal memory with practice, with and without hormone therapy. Scores were the same for those with and without hot flashes, and for women who had a uterus or had a hysterectomy.

"Estradiol initiated within six years of menopause does not affect verbal memory, executive functions, or global cognition differently than therapy begun 10+ years after menopause," the authors write. "Estradiol neither benefits nor harms these cognitive abilities regardless of time since menopause."

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions

More in Home

FDA Approves Bavencio for Merkel Cell Carcinoma

FDA Approves Bavencio for Merkel Cell Carcinoma

Drug targets the PD-1/PD-L1 pathway; first sanctioned treatment in the United States

Heterogeneous Association for Alcohol, CVD Presentation

Heterogeneous Association for Alcohol, CVD Presentation

Non-drinking linked to increased risks of unstable angina, MI, heart failure, ischemic stroke, PAD, AAA

Mobile App Cuts In-Person Visits After Breast Reconstruction

Mobile App Cuts In-Person Visits After Breast Reconstruction

Number of visits down, increase in e-mails to doctors for ambulatory patients undergoing breast recon

is free, fast, and customized just for you!

Already a member?

Sign In Now »